Search

An interview with Dr. Julian Panes, a renowned expert in inflammatory bowel disease (IBD), discusses various aspects of inflammatory bowel disease (IBD) in an interview. He highlighted the genetic predisposition, environmental factors, gut microbiome, clinical differences between ulcerative colitis and Crohn's disease, the role of diet in IBD, and the symptoms experienced by those with ulcerative colitis, emphasizing the need for a holistic assessment for diagnosis and management of IBD.

CytoReason, a tech company, has partnered with the Crohn's & Colitis Foundation to enhance their analytical capabilities in the field of inflammatory bowel disease (IBD). The collaboration will integrate the Foundation's IBD Plexus real-world data platform, which includes patient biopsies and comprehensive data, into CytoReason's disease model platform. This integration will allow for a deeper understanding of disease subtypes, the development of targeted therapies, and the generation of biomarkers for clinical trials. The partnership aims to improve the precision and effectiveness of drug development in IBD by leveraging AI and large-scale datasets. [Extracted from the article]

More than 500,000 people in the UK have inflammatory bowel disease (IBD), says IBD UK. [ABSTRACT FROM AUTHOR]

Inflammatory bowel disease (IBD) is a term that refers to two main conditions: Crohn's disease and ulcerative colitis. It is a lifelong inflammatory disorder that affects the gastrointestinal tract. Managing IBD requires a multidisciplinary team approach, and specialist IBD nurses have an important role in this, providing education, support and advocacy to patients with IBD. This article provides an overview of the symptoms of Crohn's disease and ulcerative colitis, as well as the medical, nutritional and surgical management strategies that can be used. It discusses the nurse's role in management and the importance of using a multidisciplinary team approach to provide optimum patient care and support. [ABSTRACT FROM AUTHOR]

Padagis has launched budesonide 2-mg rectal foam for patients with ulcerative colitis. The reference listed drug Uceris (Salix Pharmaceuticals), is a prescription corticosteroid that helps control mild to moderate ulcerative colitis extending from the rectum to the sigmoid colon. Investigators do not have efficacy or safety data about the use of the foam in children. [Extracted from the article]

The FDA also granted tentative approval to tofacitinib tablets, 10 mg, the generic of Pfizer's Xeljanz tablets, 10 mg. Compare To: Xeljanz The FDA has granted final approval to Zydus Lifesciences Ltd for its tofacitinib tablets, 5 mg, the generic of Pfizer Inc's Xeljanz tablets, 5 mg, to treat adults with active psoriatic arthritis and moderately to severely active rheumatoid arthritis. [Extracted from the article]

This article, which forms part of the life sciences series and is the first of two articles on the digestive system, explores the structure and function of the digestive system. It is important that nurses understand how the digestive system works and its role in maintaining health. The article describes the gross structure of the gastrointestinal tract along with relevant physiology. It also outlines several disorders of the gastrointestinal tract and their treatment and nursing management. The second article will explain the liver, pancreas and gall bladder and their digestive functions, and provides a brief overview of the disorders of chronic liver disease, pancreatitis and gallstones. [ABSTRACT FROM AUTHOR]

The article focuses on the life and works of singer, song writer and founder of the rock band Eagle, Glenn Frey, in the U.S. It chronicles how Frey established the band and his significant contribution in the music industry. It also mentions the causes of Frey's death which was due to the complications from rheumatoid arthritis, acute ulcerative colitis, and pneumonia.

Ulcerative colitis is a relapsing chronic disease that has an unpredictable course. A relapse in the condition requires timely intervention and expert monitoring. A severe flare-up will often necessitate admission to hospital. This article provides an overview of the medical management of severe ulcerative colitis and the nursing interventions required. [ABSTRACT FROM AUTHOR]

Ulcerative colitis (UC) is a chronic inflammatory bowel disease affecting the colon and rectum that is characterised by unpredictable periods of remission and relapse. Although diagnosis is not expected to occur in primary care, it can often be suspected from a physical examination and from the key clinical symptoms, caused by mucosal inflammation and ulceration, of bloody diarrhoea, rectal bleeding, mucous and urgency. Treatment goals are inducing and maintaining remission, avoiding admission to hospital and surgery, and preventing complications. 5-Aminosalicylates are the mainstay of treatment in mild-to-moderate disease. Compliance remains an important issue in disease management as non-compliant patients are at higher risk of exacerbations. Patients should be reviewed yearly. This article reviews the symptoms, treatment and management of UC. [ABSTRACT FROM AUTHOR]

The article presents information on the treatment of ulcerative colitis (UC), an inflammatory bowel disease which is caused due to intestinal infection. The major symptoms of UC are diarrhea, rectal bleeding, and abdominal pain. The patient infected from UC should be given systematic treatment, essentially with oral medication, through intravenous options that are available to them in hospitals.

The article presents the case study of a typical patient with ulcerative colitis (UC) and suggests an approach to his initial and follow-up treatment. UC and Crohn's disease comprise what is known as inflammatory bowel disease. CH is a fictitious patient. CH has no family history of bowel disease, and no significant past medical history. He has little in the way of abdominal pain, but feels "a bit queasy in the stomach" when he gets the diarrhoea. Recent antibiotic treatment could be significant, both because post-antibiotic diarrhoea is common and also because of the relatively rare pseudomembranous colitis, which can follow some antibiotic treatments, classically clindamycin.

The article discusses the management of ulcerative colitis (UC) using UCERIS (budesonide). A type of inflammatory bowel disease (IBD), IC affects the mucosal surface of the colon and rectum. Systemic glucocorticoids are used for treating acute flares of UC, as well as mild, moderate and severe active UC. Orally administered, UCERIS is an extended release tablet which has been formulated with multimatrix technology (MMX). Some of the adverse effects of the drug are headache, nausea and fatigue.

The article reports that researchers from Seoul National University in Korea investigated the ability of graphene quantum dots to help treat certain kinds of autoimmune diseases. It investigates the use of graphene quantum dots in treating inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis.

This section offers news briefs on research from nursing and scientific journals. Topics discussed include findings which revealed that hearing the mother's voice increases stability in premature babies, yoga may benefit people with inflammatory bowel disease and association of pollution with higher rates of breast cancer risk factor.

A personal narrative is presented which explores the author's experience of suffering ulcerative colitis in 2008, particularly the professionalism shown by inflammatory bowel disease nurse specialists Alan Boal and Seth Squires in caring for her.

The article focuses on the need for health care professionals to educate patients suffering from ulcerative colitis to improve their conditions. It references a new study published in the April 2013 issue of "Gastroenterology Research," reporting that many patients do not consider flare-up symptoms as a reason to visit their physician.

The article reports on research which was conducted on children and adults with Crohn's disease and ulcerative colitis in Denmark in an effort to determine the risk that patients with the diseases have of developing pulmonary embolism or deep vein thrombosis. The researchers found that patients with inflammatory bowel disease have twice the incidence of pulmonary embolism or deep vein thrombosis than the general population.

The article focuses on the inflammatory bowel diseases (IBD) wherein an estimated 1.5 million Americans have been inflicted with such condition. It notes that Crohn's disease and ulcerative colitis (UC) are often integrated with IBDs that require long-term treatment with medications. It also highlights the need to educate patients, particularly on the association of such to ocular complications. Emphasis on multidisciplinary approach to the care of the patients is also discussed.

The article reveals that a study published in "Inflammatory Bowel Diseases" has found that patients who experienced physical or sexual abuse as children are at higher risk of developing ulcerative colitis (UC) as adults.

Working as an inflammatory bowel disease specialist nurse has enabled Vicki Edge to provide continuity of care for patients with this chronic condition. In addition, the number of , outpatient appointments and inpatient bed days have been reduced. [ABSTRACT FROM AUTHOR]

This section offers news briefs relevant to the pharmaceutical industry as of August 2014. Actavis Pharma Inc.'s Delzicol (mesalamine) delayed-release capsule has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of ulcerative colitis in 12 years and older patients. Novo Nordisk's Levemir FlexTouch pre-filled insulin-delivery device has been approved by the FDA for patients with diabetes mellitus.

The National Institute for Health and Care Excellence published a clinical guideline on ulcerative colitis in June. Covering management of the condition in adults, children and young people, it says symptom relief should be the primary outcome for patients. [ABSTRACT FROM AUTHOR]

The article offers updates on topics related to gastrology. The first one is about a study that compares the effectiveness of ciclosporin and infliximab for patients with severe refractory ulcerative colitis. The other is about restrictive transfusion strategy for acute upper gastrointestinal (GI) bleeding.

The article discusses the nursing care of patients with ulcerative colitis. The author refers to the previously published article "Nursing management of patients with severe ulcerative colitis" and describes the importance of maintaining the patient's fluid balance and initiating a low fibre diet. The risk factors for developing complications such as toxic megacolon are also described.

The article presents the study led by Andrew R. Hart of Great Britain-based University of East Anglia, which showed that oleic acid reduces the risk of ulcerative colitis (UC).

The article presents the percentage of individuals with ulcerative colitis (UC) who have family member or relative with Crohn's disease or UC.

The article offers information on the study about the association of men with ulcerative colitis with increased risk for developing pancreatic neoplasia presented by Dr. Jason Schwartz at a meeting during the Digestive Disease Week in New Orleans, Louisiana held from May 1 to 5, 2010.

The article presents a response by author Mark Sephton to letters to the editor about his article concerning the management of patients with ulcerative colitis in the December 16, 2010 issue.

A letter to the editor is presented in response to the severe ulcerative colitis learning zone article by Mark Sephton in the December 16, 2009 issue.

A letter to the editor is presented in response to an article by Mark Sephton concerning the management of patients with ulcerative colitis, published in the December 16, 2009 issue.

Instructions on writing a practice profile regarding the article in this issue, "Nursing management of severe ulcerative colitis," for certificate of learning credit is presented.

A quiz for nurses concerning ulcerative colitis is presented.

The article reports that guidance from Great Britain's National Institute for Health and Clinical Excellence (NICE) recommends treatment with infliximab for acute exacerbations of ulcerative colitis. Infliximab is recommended if ciclosporin is contraindicated or clinically inappropriate. Other NICE guidance recommends febuxostat for the management of chronic hyperuricaemia in gout.

The article shows that more than 33% of patients with ulcerative colitis who would otherwise need to undergo colectomy can avoid the surgery if treated with infliximab (Remicade), according to results of extension phases of the Active Ulcerative Colitis Trials 1 and 2 at the American College of Gastroenterology meeting. Brian Feagan of the University of Western Ontario stated that infliximab infusion every 8 weeks reduced the incidence of colectomy by 36% over 54 weeks of the study compared with placebo.

The article discusses the results of a study on the effect of infliximab on ulcerative colitis, presented by Walter Reinisch at Digestive Disease Week, that included data from long-term extensions of the Active Ulcerative Colitis (ACT) 1 and 2 trials. Reinisch said that infliximab is showing the efficacy as a long-term treatment. According to the study, extended infliximab exposure is not associated with the risk of mortality or of serious infections in patients with Crohn's disease.

The article presents a pharmacological analysis of the chemistry actions, properties and effects of mesalamine, Shire Pharmaceutical's first once-daily treatment for inducing remission of mild-to-moderate ulcerative colitis (UC). It highlights the results of two clinical trials which evaluated the efficacy and safety of the drug in the induction of remission in adult patients with UC. The prescribed dosages and most common side effects reported with the drug were mentioned.

The article presents information on the management of inflammatory bowel disease (IBD). Azathioprine and its metabolite mercaptopurine maintain remission of Crohn's and ulcerative colitis. These can treat frequent relapses, or flares on withdrawal of prednisolone. Shared-care protocols should exist between hospital IBD clinics and general practitioners. Many IBD patients will take these drugs for 4-5 years. There should be a clear agreement about who is arranging full blood count monitoring.

The article presents latest research and scientific reports from the nursing and medical journals. High intakes of meat and alcohol are associated with an increased risk of relapse in ulcerative colitis and are potentially modifiable factors. Use of gastric acid suppressive therapy is associated with an increased risk of community acquired pneumonia. Reduction of gastric acid by acid-suppressive drugs allows pathogenic colonization from the upper gastrointestinal tract.

Reports on the protective effects of appendicectomy against the development of ulcerative colitis. Histological effects that promote ulcerative colitis; Incidence rates of ulcerative colitis; Risk factors of diseases.